A study testing whether a GLP-1 medicine from University of Chicago, semaglutide, can help with weight.

Who can join

Adults 18 to 75, have obesity or are overweight, BMI 30+.

What you take

semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 3.2 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation.

Primary condition: Overweight or Obesity. Also studied in: Atrial Fibrillation.

Who can join, in detail

Key inclusion criteria

• Age 18-75 years
• BMI greater than or equal to 30 kg/m2
• Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
• Ability to provide informed consent before any trial-related activities.
• Patients with type 2 diabetes mellitus (T2DM) will be included:

Key exclusion criteria

• Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening
• Current antiobesity medication use or use within the last 90 days prior to screening
• A self-reported change in body weight of > 5 kg (11 lb.) within 30 days before screening
• History of bariatric surgery
• History of type I diabetes mellitus

Where this study is enrolling

This trial has 2 US sites across 2 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2025-04-14. Expected completion: 2028-06. Last updated on ClinicalTrials.gov: 2025-11-14.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact